

RESPIRI LIMITED

RESPIRI ACCELERATING ACTIVITY

Respiri Limited (ASX: RSH) has a clear runway to progress from the demonstration prototype completion as announced on 20 April, 2018 and reiterates how the recent capital raising of \$3.0m allows the company to accelerate our activity across the stated milestones thereby optimising the execution of the plan.

At 9am today, CEO Mario Gattino will provide further insight into the significance of the milestone achievement and future development plans in a conference call as detailed below.

Conference call scheduled
Tuesday 24 April 2018 | 09.00am AEST
Telephone: 1800 123 296
Conference ID: 1296975

\$3.0M CAPITAL RAISING | USE OF FUNDS

- Development of Android platform to parity with existing iOS platform, in effect doubling the size of the target market at launch (based on current distribution of smartphones)
- Appointment of a Quality Assurance & Regulatory Manager on a contract basis to establish our Quality Management System and ISO13485 certification and facilitate regulatory approvals in target launch markets
- Early collaboration with identified Australian manufacturer to facilitate a smooth transfer from developers to high capacity manufacturing capabilities (e.g. purchase of new tooling, bulk quantities of components, batch testing etc.)
- Review and expansion of our multifaceted intellectual property by registering new patents, adding to our existing trade secrets and proprietary information, trademarks and copyright, ensuring highest barriers to competition in the geographies where we choose to launch
- Planning launch strategy - e.g. market research, online platform strategy, consumer and media campaigns, promotional materials, partnerships, distribution, brand ambassadors, asthma association support / collaboration
- Appointment of a UK based Business Development Manager on a contract basis to facilitate and expedite observational, real world community studies of the AirSonea Gen II compared to current practice

- Progress development of the overnight monitor which will be a major addition to the product portfolio, with the company ensuring the timing of finalisation and planned launch follows smoothly after the successful launch of the AirSonea Gen II

PRODUCT DEVELOPMENT TO MANUFACTURE READY

The next phase of product development is testing and enhancements of the demonstration prototype with final design slated for end Q3 followed by validation and verification and pre-production planning to ensure the medical device can be manufactured in large quantities. The company is on track to achieve the highest quality standards and obtain regulatory approval in target markets for a planned commercial launch in Q1/2019.

DIGITAL MEDTECH CONFERENCE, SAN FRANCISCO




A stated milestone for the company is our attendance at major industry trade shows and healthcare conferences, which was targeted for Q3. Today, CEO, Mario Gattino will conduct the conference call with investors just prior to the start of “The Digital Medtech Conference” in San Francisco. The delivery of the demonstration prototype allows Mr Gattino, along with Chairman, Leon L’Huillier, also attending the conference, to introduce the product to leading global experts, innovators and key decision makers who have come together with the common goal of industry networking and development of digital health devices, tools and services.

Following the conference, the Chairman and CEO will take further meetings within the US and then travel to the UK, demonstration product in hand, to discuss the opportunity with health bodies, clinicians, key opinion leaders, investors and industry partners.

VIDEO CASE STUDY | PARENTS OF CHILDREN WITH ASTHMA

In the first of our new product videos, hear from the family who has been trialling the AirSonea product. Eight-year-old Lachlan was diagnosed with asthma as a toddler. Wheeze monitoring and the diligent use of the product's electronic diary has provided the peace of mind that they can take action prescribed by their doctor and anticipate an asthma event. Importantly, the product has helped them identify the environmental factors that cause Lachlan to develop wheeze and other asthma symptoms giving them a chance to avoid or prepare for those triggers. The video is available for viewing at respiri.co.



-End-

Contact:

Mario Gattino
CEO & Director
1800 476 632

About Respi Limited (ASX:RSH)

Respi is a health technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun. Respi is especially proud of its recent de-risking of milestones. The substantial achievements over the past 18 months place Respi in a lower risk position and on the cusp of commercialisation compared to the vast majority of medical device and biotech companies

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.